Service pharmacie, hôpital du Gier, 19, rue Victor-Hugo, 42400 Saint-Chamond, France.
Unité de gestion du risque infectieux, service d'infectiologie et service des agents infectieux et hygiène, CHU de Saint-Étienne, 42055 Saint-Étienne cedex 2, France.
Med Mal Infect. 2019 May;49(3):208-213. doi: 10.1016/j.medmal.2018.10.009. Epub 2018 Nov 20.
To measure the impact of the differences between recommended daily average maintenance doses and defined daily doses on antimicrobial consumption indicators (amoxicillin+amoxicillin-clavulanic acid).
We calculated the impact of the antibacterial agent switch or de-escalation and reviewed the consumption indicators of our French hospital with defined daily doses (DDD) of 3g. We also applied these DDDs to French and European community setting indicators in private practice.
We observed a modification in trend consumption indicators over a 10-year period: indicator stability for our hospital (-0.32% versus +5.45%), decrease for French community indicators (-9.9% versus +6.7%). The recalculated 2015 data for European community indicators showed France as the 9th largest European consumer (versus 4th position before).
DDDs must be modified to have appropriate indicators to evaluate antimicrobial stewardship programs and to penalize prescriptions favoring the emergence of resistant pathogens.
衡量推荐的日平均维持剂量与限定日剂量之间的差异对抗菌药物消耗指标（阿莫西林+阿莫西林-克拉维酸）的影响。
我们计算了抗菌药物转换或降级的影响，并对我们医院的抗菌药物消耗指标进行了审查，该医院的限定日剂量（DDD）为 3g。我们还将这些 DDD 应用于法国和欧洲社区私人执业的设定指标。
我们观察到 10 年间趋势消耗指标的变化：医院指标稳定（-0.32%对+5.45%），法国社区指标下降（-9.9%对+6.7%）。重新计算的 2015 年欧洲社区指标数据显示，法国是欧洲第 9 大抗菌药物消费国（之前为第 4 位）。
必须修改 DDD 以获得适当的指标，以评估抗菌药物管理计划，并对有利于耐药病原体出现的处方进行处罚。
